Narayana Hrudayalaya growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+44.0%+9.3%+10.9%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+26.7%+10.8%+19.3%
+17.1%+9.7%+20.4%
+1.9%+0.1%+30.2%
+2.0%+0.1%+30.2%
+71.7%+29.2%+35.1%
+25.1%+25.8%+35.3%
+63.5%−7.2%−1.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NH₹1,714.50

Narayana Hrudayalaya Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISNEULANDLABNATCOPHARMLALPATHLABSAILIFECOHANCEMcap ₹35,038 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+10.9+9.3+44.0—
EBITDA Growth—+19.3+10.8+26.7—
EBIT Growth—+20.4+9.7+17.1—
Net Income Growth—+30.2+0.1+1.9—
EPS Growth—+30.2+0.1+2.0—
Total Assets Growth—+35.1+29.2+71.7—
Total Equity Growth—+35.3+25.8+25.1—
Cash from Operations Growth—-1.7-7.2+63.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.